Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19

Current standard treatment of COVID-19 lacks in effective antiviral options. Plitidepsin, a cyclic depsipeptide authorized in Australia for patients with refractory multiple myeloma, has recently emerged as a candidate anti-SARS-CoV-2 agent. The aim of this review was to summarize current knowledge...

Descripción completa

Detalles Bibliográficos
Autores principales: Papapanou, Michail, Papoutsi, Eleni, Giannakas, Timoleon, Katsaounou, Paraskevi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306251/
https://www.ncbi.nlm.nih.gov/pubmed/34357135
http://dx.doi.org/10.3390/jpm11070668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306251/
https://www.ncbi.nlm.nih.gov/pubmed/34357135
http://dx.doi.org/10.3390/jpm11070668

Ejemplares similares